Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Early-Stage Unfavorable Classical Hodgkin Lymphoma. The trial aims to explore a new treatment approach that includes a medication called Tislelizumab, which is a form of immunotherapy. Immunotherapy is a treatment that helps the body's immune system fight cancer. The study will also use other medications, including Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride, which are commonly used in cancer treatment. These medications will be given as infusions, which means they are delivered directly into the bloodstream through a vein.

The purpose of this study is to find out how effective and well-tolerated this new treatment plan is for patients with this type of Hodgkin Lymphoma. The study will follow a specific plan where patients will receive the medications over a period of time. The treatment will be guided by a special type of scan called a PET scan, which helps doctors see how the cancer is responding to the treatment. The study will last for several years, and patients will be monitored to see how well they do over time.

Participants in the study will receive either the new treatment plan or a standard treatment, which may include a placebo. The study will look at various outcomes, such as how long patients remain free from cancer progression and their overall survival rates. It will also consider the quality of life reported by the patients during and after the treatment. The goal is to provide a more personalized treatment option for patients with this type of cancer, potentially improving their outcomes and quality of life.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the clinical trial, an initial assessment will be conducted to confirm eligibility. This includes reviewing medical history and conducting necessary tests to ensure the trial is suitable for participation.

  2. Step 2

    Treatment plan discussion

    A detailed discussion about the treatment plan will take place. This includes information about the medications, their purpose, and the schedule for administration.

  3. Step 3

    Medication administration

    The treatment involves the administration of several medications through infusion. These medications include dacarbazine, tislelizumab, vinblastine sulfate, and doxorubicin hydrochloride. Each medication will be given according to a specific schedule determined by the healthcare team.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring will be conducted to assess the response to treatment and manage any side effects. This includes scheduled visits for physical examinations, blood tests, and imaging studies as needed.

  5. Step 5

    Completion of treatment

    Upon completion of the treatment regimen, a final assessment will be conducted to evaluate the overall response to the therapy. This includes a review of all test results and a discussion about the next steps in care.

  6. Step 6

    Long-term follow-up

    Long-term follow-up will be scheduled to monitor health status and ensure any late effects of treatment are managed appropriately. This may involve periodic check-ups and additional tests as recommended by the healthcare team.

Who can join the trial?

12 criteria

  • Age between 18 and 60 years on the day of signing the consent form.
  • For an exploratory group, age 61 years or older on the day of signing the consent form.
  • Eligible for 4 cycles of AVD chemotherapy (exploratory group only).
  • Total CIRS-G score less than 10 and score 3 or less for each organ system. Note: Certain conditions related to Hodgkin Lymphoma are not counted in this score (exploratory group only).
  • First diagnosis of Hodgkin Lymphoma confirmed by a tissue sample.
  • No previous treatment for Hodgkin Lymphoma, except for corticosteroids if needed.
  • Early-stage unfavorable Hodgkin Lymphoma as defined by specific criteria, including certain stages and risk factors.
  • Able to provide written consent and agree to follow the trial requirements, including using contraception and attending scheduled assessments.
  • Estimated life expectancy of more than 3 months.
  • Adequate organ function as shown by specific medical tests, with exceptions for conditions related to Hodgkin Lymphoma.
  • For women who can have children: Must use effective birth control, not breastfeed, and have a negative pregnancy test before starting the trial.
  • For men who are not sterile: Must use barrier methods like condoms for birth control and not donate sperm during the trial and for 6 months after the last treatment.

Who cannot join the trial?

13 criteria

  • Patients who have a different type of cancer other than Early-Stage Unfavorable Classical Hodgkin Lymphoma.
  • Patients who are younger than 18 years old or older than 60 years old.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a serious infection that is not controlled.
  • Patients who have a history of another cancer within the last 5 years, except for certain skin cancers or in situ cervical cancer.
  • Patients who have an autoimmune disease, which is when the body's immune system attacks its own healthy cells.
  • Patients who have received a live vaccine within 30 days before starting the study treatment.
  • Patients who have a known allergy to the study drug or its ingredients.
  • Patients who have a history of heart disease that is not well controlled.
  • Patients who have a history of lung disease that is not well controlled.
  • Patients who have a history of liver disease that is not well controlled.
  • Patients who have a history of kidney disease that is not well controlled.
  • Patients who are currently participating in another clinical trial.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tislelizumab is a type of medication known as a checkpoint inhibitor. It works by helping your immune system recognize and attack cancer cells more effectively. In this trial, tislelizumab is being used as part of a personalized treatment plan for patients with early-stage unfavorable Hodgkin Lymphoma. The goal is to see if adding tislelizumab to the treatment can improve outcomes for patients by stopping the cancer from growing or spreading for at least a year.

What is already known about the treatment

Tislelizumab – Tislelizumab is administered as an intravenous infusion, meaning it is given directly into the bloodstream through a vein. It is currently being studied in clinical trials for its effectiveness in treating early-stage unfavorable classical Hodgkin lymphoma, a type of cancer. The medication works by blocking a specific protein on the surface of immune cells, which helps the body's immune system recognize and attack cancer cells more effectively. Tislelizumab is classified as an immune checkpoint inhibitor, a type of drug that helps boost the immune response against cancer.

Investigated diseases

Early-Stage Unfavorable Classical Hodgkin Lymphoma – This is a type of cancer that originates in the lymphatic system, specifically affecting a type of white blood cell called lymphocytes. It is characterized by the presence of Reed-Sternberg cells, which are large, abnormal lymphocytes. In its early stages, the disease is typically localized to a limited number of lymph nodes or a single region of the body. As it progresses, it can spread to other lymph nodes and organs, such as the spleen, liver, or bone marrow. The disease is termed "unfavorable" due to certain risk factors that may include large tumor size or involvement of multiple lymph node regions. The progression of the disease can vary, but it generally involves the gradual spread of cancerous cells through the lymphatic system.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-500571-32-00Protocol codeUni-Koeln-4470Estimated enrolment120 patientsSponsorUniversity Of Cologne

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.